Oppenheimer Asset Management Inc. Purchases 23,159 Shares of Novo Nordisk A/S $NVO

Oppenheimer Asset Management Inc. raised its position in Novo Nordisk A/S (NYSE:NVO) by 4.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 493,724 shares of the company’s stock after purchasing an additional 23,159 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $34,077,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Copeland Capital Management LLC raised its position in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $27,000. Stone House Investment Management LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $30,000. Disciplina Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 297 shares during the period. Finally, Dagco Inc. acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $35,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on NVO. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price for the company in a report on Wednesday, August 13th. Finally, Dbs Bank upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $76.00.

Novo Nordisk A/S Trading Down 0.4%

Shares of Novo Nordisk A/S stock opened at $53.02 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $114.19. The stock has a 50 day moving average price of $56.56 and a two-hundred day moving average price of $62.40. The stock has a market capitalization of $236.74 billion, a PE ratio of 14.57, a price-to-earnings-growth ratio of 2.41 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were given a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s payout ratio is presently 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.